Coronary Artery Disease Screening in Patients With Chronic Kidney Disease (EVACKD)

May 6, 2026 updated by: University Hospital, Grenoble

Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease

Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

283

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • France
    • France
      • La Tronche, France, France, 38700

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients from the University Hospital of Grenoble

Description

Inclusion Criteria:

  • Male or female patients aged over 18 years
  • Affiliated with the French social security system
  • Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
  • Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
  • Having expressed no objection to participation in this study

Exclusion Criteria:

  • Legally protected adult (Article L1121-8 of the French Public Health Code)
  • Person deprived of liberty (Article L1121-8 of the French Public Health Code)
  • Pregnant woman
  • Patient who has undergone a normal coronary exploration within the past year

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging
Time Frame: 2-year follow-up
Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.
2-year follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint
Time Frame: 2 years
To evaluate each component separately : Cardiac mortality rate, non-fatal myocardial infarction rate, non-fatal ischemic stroke rate, hospitalization rate for heart failure, and all-cause mortality rate.
2 years
To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE)
Time Frame: At 1-year and 2-year follow-up
Rate of patients with Major Adverse Kidney Events (MAKE), defined by the composite endpoint of death, dependence on renal replacement therapy, and a ≥50% decline in estimated glomerular filtration rate (eGFR) from baseline
At 1-year and 2-year follow-up
To assess the number of Acute Kidney Injury (AKI) events during follow-up
Time Frame: 2 years
Evaluation of the Acute Kidney Injury (AKI) rate classified into three grades: Grade 1 (1.5- to 2-fold increase in serum creatinine), Grade 2 (2- to 3-fold increase), and Grade 3 (>3-fold increase or need for dialysis)
2 years
To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention
Time Frame: 2 years
Performed by calculating the rate of revascularization by coronary artery bypass grafting or percutaneous coronary intervention
2 years
To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA)
Time Frame: 2 years
Rate of ischemic heart disease without significant coronary artery stenosis (INOCA)
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Grenoble

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

November 30, 2027

Study Completion (Estimated)

January 31, 2028

Study Registration Dates

First Submitted

May 6, 2026

First Submitted That Met QC Criteria

May 6, 2026

First Posted (Actual)

May 14, 2026

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 6, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 38RC25.0302 (Other Identifier: CHU Grenoble Alpes)
  • IDRCB 2025-A02537-42 (Other Identifier: ANSM (Agence nationale de sécurité du médicament et des produits de santé))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe